In the current era of rapid technological advancement, the in vitro diagnostics (IVD) industry is undergoing profound changes, with the alternation of new and old products becoming a significant feature of the industry's development process. This alternating process is like a double-edged sword, bringing many opportunities and challenges to the IVD industry, profoundly affecting the industry landscape, enterprise operations, and market supply and demand at multiple levels.

 

Reshaping the Market Landscape

 

1. Consolidation or change of advantages of top enterprises

 

For top IVD companies that have already established a position in the market, the transition between new and old products is both an opportunity to consolidate their advantages and a potential challenge. Powerful enterprises often have strong R&D teams and sufficient funds, which can quickly respond to market demand and launch innovative new products. In the field of molecular diagnostics, some leading companies have launched new generation sequencing products with advanced technology, which have greater advantages compared to traditional PCR diagnostic products. Once these new products are launched, they can attract more customers, further expand market share, and consolidate their position in the industry. But if top companies make mistakes in the direction of new product development or fail to keep up with new technological trends in a timely manner, their market share may be seized by emerging companies with more competitive new products, and their advantageous position may be impacted.

 

Biological buffer MOPSO

 

2. Opportunities and crises coexist for small and medium-sized enterprises

 

Small and medium-sized enterprises are facing a more complex situation in the wave of new and old product alternation. On the one hand, if small and medium-sized enterprises can focus on segmented markets, grasp the needs of specific customer groups, and develop new products with differentiated advantages, they may achieve overtaking in the curve. For example, some small and medium-sized enterprises focused on the POCT (point of care testing) field have developed portable diagnostic devices that are easy to operate and have fast detection speeds to meet the demand for convenient and fast diagnostic products in the grassroots market. They have quickly opened up a market position in the grassroots market and enhanced their own market position. On the other hand, many small and medium-sized enterprises face numerous difficulties in developing new products due to limitations in funding, technology, and talent reserves. When the mainstream market transitions to new products, if they cannot update their products in a timely manner and still rely on old products, these enterprises may gradually be marginalized by the market due to the decline in product competitiveness, and even face the crisis of being eliminated.

 

Technological innovation acceleration

 

1. Drive an increase in research and development investment

 

The transition between new and old products has prompted IVD companies to increase their research and development investment. In order to stand out in the competition, enterprises need to constantly explore new technologies and methods to develop new products with better performance. After the rise of chemiluminescence immunoassay technology, many enterprises have invested a lot of funds in the research and development of new luminescent substrates, optimization of detection systems, etc. in order to occupy a place in this field.

 

2. Generate new technological breakthroughs

 

During the transition between new and old products, different technological routes collide with each other, creating conditions for new technological breakthroughs. In the field of gene sequencing, every product iteration is accompanied by technological innovation, from traditional Sanger sequencing technology to the new generation of high-throughput sequencing technology, and to the currently being explored single-molecule sequencing technology. With the increasing demand for sequencing speed, accuracy, and cost in the market, companies are constantly trying new technological paths when developing new products, such as the development of nanopore sequencing technology, which is expected to achieve faster and lower cost gene sequencing. Once this technological breakthrough is achieved, it will change the pattern of the gene diagnosis market and bring new growth points to the IVD industry.

 

Challenges faced by enterprise operations

 

1. Difficulties in production and inventory management

 

During the transition between new and old products, enterprises face significant challenges in production and inventory management. On the one hand, we need to gradually reduce the production scale of old products while orderly increasing the output of new products. However, in practical operation, due to the unpredictable changes in market demand, there may be a backlog of old product inventory, occupying a large amount of funds and storage space, and insufficient production capacity for new products, which cannot meet market demand in a timely manner.

 

2. Market promotion and customer pressure

 

New products entering the market require a lot of market promotion work. Compared with old products, new products often adopt new technological principles or testing methods, and customer acceptance takes time.

 

At present, the alternation of new and old products has triggered a series of chain reactions in the IVD industry, from market restructuring and accelerated technological innovation to operational challenges and supply chain adjustments. These impacts not only bring new opportunities for industry development, but also raise many urgent problems that need to be solved. IVD enterprises can only seize opportunities in the wave of new and old product alternation by actively responding, continuously improving their comprehensive strength, and strengthening upstream and downstream cooperation in the industry.

 

enzyme preparation

 

As an upstream IVD reagent raw material manufacturer, Hubei Xindesheng Company can supply a full range of products including biological buffering agents, color reagents, luminescent reagents, enzyme preparations, etc. In the field of biological buffering agents, it covers various types such as HEPES and Tris, with a wide pH buffering range to meet the needs of different experimental and detection scenarios; TOOS, MAOS and other products in color reagents have sensitive color development and good stability. Through full process quality control and advanced production technology, Xindesheng provides downstream IVD enterprises with stable and diverse raw material choices. If you have any purchasing needs, please feel free to contact Xindesheng at any time!